Braveheart Bio's final prospectus, dated August 5, 2026, prices 21,250,000 shares at $18.00 each. Net proceeds are estimated at $351.2 million, and the company's accumulated deficit was $80.3 million at March 31, 2026.
Braveheart Bio, Inc. filed a Form S-1 on July 15, 2026 for an initial public offering on The Nasdaq Global Market under the symbol BRVE. The preliminary prospectus leaves the share count and price blank, and names Goldman Sachs & Co. LLC and Jefferies as joint bookrunners.
Questions about Braveheart Bio
When did Braveheart Bio go public?
Our latest story on this, dated Aug 6, 2026: "Braveheart Bio prices IPO of 21,250,000 shares at $18.00". The story links the filing or release it is based on. Read the story.
Has Braveheart Bio raised money recently?
Our latest story on this, dated Jul 15, 2026: "Braveheart Bio files for IPO, plans Nasdaq Global Market listing as BRVE". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Braveheart Bio?
Braveheart Bio, Inc. trades under the ticker BRVE on NASDAQ.
Where is Braveheart Bio listed?
Braveheart Bio, Inc. is listed on NASDAQ.
What is the SEC CIK of Braveheart Bio?
The SEC Central Index Key (CIK) for Braveheart Bio, Inc. is 2131524. Its filings are on SEC EDGAR.
How many shares does Braveheart Bio have outstanding?
90,038,969 shares as of 2026-09-03, per the cover page of its 10-Q filed 2026-09-08.
Which country or territory is Braveheart Bio listed under?
Our directory records Braveheart Bio, Inc. under United States.
What does Braveheart Bio do?
Our directory classifies Braveheart Bio, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
What is the ISIN of Braveheart Bio?
The ISIN recorded for Braveheart Bio, Inc. is US10567X1019.
Does aibio.space cover Braveheart Bio?
aibio.space lists Braveheart Bio, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Braveheart Bio incorporated?
SEC records list its state or country of incorporation as DE.
What is the latest Braveheart Bio (BRVE) stock news?
Our latest story on Braveheart Bio, dated Aug 6, 2026: "Braveheart Bio prices IPO of 21,250,000 shares at $18.00". Braveheart Bio's final prospectus, dated August 5, 2026, prices 21,250,000 shares at $18.00 each. Net proceeds are estimated at $351.2 million, and the company's accumulated deficit was $80.3 million at March 31, 2026. Source.
Is Braveheart Bio a smaller reporting company?
SEC records list Braveheart Bio, Inc.'s filer category as: Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company.
Where is Braveheart Bio headquartered?
SEC records list its business address as ONE LETTERMAN DR., SAN FRANCISCO, CA, 94129.
When does Braveheart Bio's fiscal year end?
Braveheart Bio, Inc.'s fiscal year ends on December 31, per SEC records.
Investor discussion: Braveheart Bio
Members talk about Braveheart Bio (BRVE). Reader posts, not aibio.space reporting, and not investment advice.
Rules
Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.
Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.
Capital-markets timeline
Financings, listing notices, splits, legal actions and other investor events at Braveheart Bio, newest first. Each line links the filing it comes from.
Financings
Filed a final prospectus for a securities offering. SEC Form 424B4. Source
Financings
Filed a registration statement for a share offering. SEC Form S-1. Source
Stock chart
Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:BRVE on TradingView.
SEC filings and registration
SEC name
Braveheart Bio, Inc.
CIK
2131524
Industry (SIC)
Pharmaceutical Preparations (2834)
US tickers
BRVE (Nasdaq)
State or country of incorporation
DE
Fiscal year ends
December 31
Filer category
Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Business address
ONE LETTERMAN DR., SAN FRANCISCO, CA, 94129
Phone
(415) 707-6312
Shares outstanding
90,038,969 as of 2026-09-03 (10-Q filed 2026-09-08)
Recent filings (8-K and 6-K are the company's own announcements)
Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.
Listing details
Braveheart Bio, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker BRVE, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.
Published and maintained by aibio.space. Not investment advice. How we work.
Who manages this pageThis page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio